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CASE REPORT Open Access
Burning pain secondary to clozapine use: a case
report
Bradley Linton1, Rachel Fu1, Penny A MacDonald2,3 and Hooman Ganjavi4*
Abstract
Background: The first of the atypical antipsychotics introduced in the 1970s, clozapine remains the most
efficacious neuroleptic to this day. However, serious and potentially fatal side effects have necessitated careful
regular monitoring among prescribing clinicians. Some adverse effects (e.g. ischaemic bowel) remain under
recognized, while newly identified adverse effects continue to be described in the literature.
Case presentation: In this report, we describe a healthy 43-year old Caucasian male who experienced onset of a
full body deep burning pain several months after the onset of treatment with clozapine. The pain worsened over
time, ceased with cessation of treatment, and returned soon after the patient was rechallenged.
Conclusion: We describe an unusual adverse effect from clozapine treatment that has not been described
elsewhere to our knowledge. We present the time course of the pain symptom, relationship to dose, associated
laboratory results, and ultimately how it was dealt with and how it improved for the benefit of clinicians who may
encounter it in the future.
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Background
Despite its superior efficacy [1-3], clozapine remains an
underutilized medication due to serious and potentially
life-threatening adverse effects [4]. Although pain has
been described as an adverse effect of clozapine, it is
usually in the context of cardiac effects [5], colitis [6],
serositis [7], or other well-described complications of
clozapine use. Here, we describe an unusual presentation
of a deep, full-body burning pain that did not appear to
be associated with any of the well-described adverse
effects of clozapine. We describe the clinical presenta-
tion, potential mechanisms, and how this adverse effect
was managed.
Case presentation
MT, a 44 year old Caucasian male with a several year
history of psychotic depression, was admitted to hospital
for treatment on March 17, 2012. His medical history
was significant for chronic headaches, degenerative disc
disease in the cervical spine, remote knee arthroscopy,
and spontaneous pneumothorax in 1996. None of these
medical issues were felt to be contributing to his psychi-
atric presentation. MT was a smoker, but did not use
other drugs or alcohol. Physical examination including
screening neurological examination did not reveal any
abnormalities. Up until recently, MT was living a fairly
functional life. He was married with two children,
previously worked in the military, and was working as
a security guard until his hospitalisation. He did not
appear to have any significant psychiatric difficulties
earlier in his life.
MT’s mood was depressed and he met the Diagnostic
and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV) for a Major Depressive Episode. He
had been depressed since early 2011 and felt it was
largely related to the end of his marriage. MT reported
that the auditory hallucinations began several months
after the onset of depression, and at a time when he
was particularly isolated and the depression quite
severe. MT reported that he hadn’t had hallucinations
prior to the onset of his depression.
MT’s psychotic symptoms manifested as a single male
voice making derogatory comments about him, and
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telling him to hurt other people. He was also troubled
by violent imagery in his mind. He never experienced
any somatic delusions or coenesthetic hallucinations. He
had previously been tried on risperidone, quetiapine,
olanzapine, and haloperidol. During this stay, the patient
was started on clozapine (March 20, 2012) and titrated
up to 500 mg daily dose prior to discharge. This was the
first time the patient had a trial of clozapine. Clozapine
is not an approved treatment for psychotic depression,
so the treatment was considered an off-label use of the
medication. At the time of discharge, the patient was
also on quetiapine 50 mg four times daily and quetiapine
200 mg nightly as needed. Aside from excessive salivation
and mild constipation, the patient appeared to tolerate the
medications well. The patient found this regimen to be
effective at controlling his auditory hallucinations and was
discharged on April 13, 2012. Depression was managed
with venlafaxine XR 225 mg daily.
MT claims that a few months after discharge he expe-
rienced a “burning pain” which awoke him in the middle
of the night. He claims it happened once or twice per
week and would last for approximately five to 10 minutes,
the longest episode lasting approximately 30 minutes. The
pain was described as a “head to toe, crippling burning
pain” in his “bones” that sometimes caused him to writhe
on the cool floor in attempt to achieve some relief. The
pain progressively became more frequent and longer in
duration, causing MT to discontinue clozapine between
the time of August 27 and September 25 of 2012. The
patient reports that after the medication was stopped, this
pain did not return. The only other medication the patient
was on at this time was venlafaxine XR 300 mg daily.
Interestingly, the patient was diagnosed with a stomach
infection during the same time and was prescribed a
course of antibiotics. The patient denied any constipation
during this time. According to the patient, during this
period, he was experiencing frequent bouts of “dry
heaving” whenever he would consume any solid food.
He stated that no food would come up during these
heaving fits, but thick mucus would sometimes be
expelled. MT’s blood work from April 25, 2012 to
October 18, 2012 often showed elevated leukocytes and
neutrophils. His leukocytes went as high as 18.8 × 109/L
and neutrophils 14.7 × 109/L on May 30, 2012.
MT restarted the clozapine shortly after an outpatient
appointment with his psychiatrist on September 25, 2012.
He started taking clozapine again at 200 mg at bedtime
and was titrated back up to his usual dose of 500 mg.
During this re-challenge, MT experienced similar pain
as he had previously and immediately stopped using
clozapine.
MT tried other antipsychotics which were not effective
in controlling his auditory hallucinations and stopped
using medications altogether. Eventually, he returned to
hospital on April 2, 2013 when he was admitted with
worsening intolerable auditory hallucinations.
During this admission MT was rechallenged on cloza-
pine since it was the only medication shown to effectively
reduce the auditory hallucinations. Clozapine was initiated
at 25 mg at bedtime on April 3, 2013 and titrated up to
400 mg at bedtime on April 22, 2013 when the pain
returned. The patient described the pain as the same pain
he experienced before, a burning, head to toe sensation
that lasted approximately two to three minutes.
A clozapine level was drawn at on April 23, 2013, but
was unremarkable (clozapine =612 nmol/L; norclo-
zapine =544 nmol/L). Other bloodwork from April 23
was also unremarkable (leukocytes =8.6 × 109/L; eryth-
rocytes =5.12 × 1012/L; neutrophils =5.7 × 109/L; lympho-
cytes =2.1 × 109/L). However, the previous bloodwork on
April 15, 2013 showed elevated leukocytes (12.0 × 109)
with elevated neutrophils (8.8 × 109). This was an isolated
circumstance of increased leukocytes during this admis-
sion. MT was also using quetiapine 100 mg every two
hours when needed and olanzapine 20 mg daily at the
time of the reaction.
MT’s dose of clozapine was decreased on April 23 to
350 mg at bedtime then increased again to 400 mg at
bedtime on April 24 which he was able to tolerate. The
bedtime dose was not further increased from 400 mg.
The total dose of clozapine was increased to 500 mg,
but split with 100 mg given in the morning and 400 mg
given at bedtime. MT did not experience any pain on
this regimen and was discharged on May 6, 2013 with
instructions to increase the clozapine to 200 mg in the
morning and 400 mg at bedtime.
On June 7, at an outpatient follow-up appointment,
MT reported the full body burning pain sensation was
once again occurring sporadically on certain nights of
the week. He also reported that the symptoms of dry
heaving and abdominal pain had returned as well, simi-
lar to the symptoms he previously described.
It seemed to the treating team that MT’s reaction could
be concentration dependent as the reaction always occurs
within hours after the patient administering his clozapine
dose. This is consistent with the time to maximum
concentration of clozapine which is cited as 2.5 hours
(1–6 hour range) [8]. This theory led to his treating team
dividing the dose while he was admitted in an attempt to
prevent the reaction from occurring. While dividing the
dose reduced his pain during his admission, the pain
appeared to have worsened since his discharge.
MT is currently working during the nights and some-
times takes two doses within close proximity to each other
due to his work schedule. These times appeared to
coincide with the times MT experienced the worst pain.
We encouraged MT to keep a log of when he experienced
pain to better understand the pattern of occurrence.
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There are also many documented cases of infections
leading to increased serum concentrations of clozapine
[9-12]. MT’s gastric infection could have increased the
serum concentration of clozapine at the time, worsening
the burning pain. The infection was treated; however, a
high neutrophil count persisted throughout his treat-
ment course in 2012. He also had an increased neutro-
phil count on April 15, 2013, which was just prior to the
return of the burning pain during the re-challenge while
admitted in hospital. It is possible that there is an associ-
ation between increased neutrophils and this patient’s
“deep, burning, bone pain.” The mechanism behind this
reaction is unknown; however, a Naranjo score of 7
(Table 1) would suggest that clozapine is probably the
cause of this patient’s bone pain. An elevated c-reactive
protein (CRP) level in October 2012 (6.3 mg/L) is
consistent with an inflammatory process. There are no
other CRP levels to compare this to. Further investiga-
tions would be beneficial to determine if inflammation
could be contributing to the pain response, and what
type of inflammation is occurring. There are reports of
polyserositis occurring with clozapine [7], but MT’s
clinical picture was somewhat different given that pain
was the only symptom he described. There was no
evidence of fever, shortness of breath, or gastrointestinal
symptoms, which are symptoms commonly described in
serositis.
The treating team also considered whether MT’s pain
symptoms could be somatic delusions or coenesthetic
hallucinations. We felt this was unlikely as MT was
frustrated at the possibility of having to discontinue
clozapine given that it was the medication that helped
him the most. We also observed that no other side
effects MT experienced from medication were unusual.
MT reported common predictable side effects such as
rigidity from risperidone, sedation from olanzapine,
and excessive salivation from clozapine. We felt that
MT’s reporting of side effects was reliable. The only
convincing psychotic symptoms were the auditory
hallucinations.
MT’s most recent out-patient appointment was on
August 9, 2013. He reported to still be experiencing
the pain, but able to tolerate it. He reported the pain
was less intense than what he previously experienced.
His log was beneficial as it confirmed that the pain
was worse when two doses of 200 mg and 400 mg
were taken close together. He is currently using
400 mg at bedtime and 200 mg in the morning. He
also eliminated one weekly dose when he transitions
from night shifts to day shifts to avoid two doses
taken in close proximity, and this appears to have
been beneficial.
Conclusion
To our knowledge, this is the first known case of
unexplained full body burning pain associated with
clozapine use. Although it is not possible to say with
absolute certainty that clozapine caused this symptom,
the association is highly probable. The pain subsided
upon cessation of the medication on two separate
occasions. The pain appears to be dose-dependent and
was most severe when serum levels would be highest.
Finally, the pain improved when doses above 400 mg
were split into lower doses. The mechanism is un-
known, but may be related to an inflammatory process.
Clinicians should be aware of this infrequent but sig-
nificant side effect and could attempt using divided
doses to minimize the severity. The seriousness of this
side effect is not known; hence, careful monitoring of
any patient with pain of unknown origin would be
warranted.
Consent
The patient has given his consent for this case report to
be published.
Table 1 Naranjo score for clozapine-induced pain
Question Answer Score
1. Are there previous conclusive reports on this reaction? No 0
2. Did the adverse event occur after the suspected drug was administered? Yes 2
3. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? Yes 1
4. Did the adverse reaction reappear when the drug was readministered? Yes 2
5. Are there alternative causes (other than the drug) that could have on their own caused the reaction? Don’t know 0
6. Did the reaction reappear when a placebo was given? Don’t know 0
7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? No 0
8. Was the reaction more severe when the dose was increased or less severe when the dose was decreased? Yes 1
9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure? Yes 1
10. Was the adverse event confirmed by any objective evidence? No 0
Total 7
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